A Nonopioid procedure for outpatient opioid detoxification

Journal of Addiction Medicine

Volumn 5, Issue 2, 2011, Pages 110-114

  Ockert, David M ^a   Volpicelli, Joseph R ^b   Baier Jr , Armin R ^a   Coons, Edgar E ^c   Fingesten, Alexandra ^a  

^a Parallax Center Inc   (United States)

^b Institute of Addiction Medicine Inc   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

2 adrenergic agonist; Clonidine; Lorazepam; Methylphenidate; Modafinal; Naltrexone; Opioid detoxification; Outpatient detoxification; Trazodone

Indexed keywords

CLONIDINE; LORAZEPAM; METHYLPHENIDATE; MODAFINIL; NALTREXONE; TRAZODONE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BENZHYDRYL DERIVATIVE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; CENTRAL STIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEMOGRAPHY; DRUG DETOXIFICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OPIATE ADDICTION; OUTPATIENT; PATIENT MONITORING; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; WITHDRAWAL SYNDROME; ADOLESCENT; DRUG COMBINATION; DRUG DEPENDENCE TREATMENT; HEROIN DEPENDENCE; METHODOLOGY; MIDDLE AGED; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADULT; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; CLONIDINE; DRUG THERAPY, COMBINATION; FEMALE; GABA MODULATORS; HEROIN DEPENDENCE; HUMANS; LORAZEPAM; MALE; METHYLPHENIDATE; MIDDLE AGED; NEW YORK; OPIOID-RELATED DISORDERS; OUTPATIENTS; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE ABUSE TREATMENT CENTERS; TRAZODONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052184198     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3181e518cc     Document Type: Article

References (21)

1. American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Association, 2000.
2. Beck AT, Ward C, Mendelson M. Beck Depression Inventory (BDI). Arch Gen Psychiatry 1961;4:561-571.
3. Collins ED, Kleber HD. Opioids: Detoxification. In: Galanter M, Kleber HD, eds. The American Psychiatric Publishing Textbook of Substance Abuse Treatment. Washington, DC: American Psychiatric Press, Inc., 2004:265-289.
4. Collins ED, Kleber HD, Whittington RA, et al. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction. JAMA 2005;294:903-913. (Pubitemid 41215459)
5. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Arch Gen Psychiatry 2006;63:210-218. (Pubitemid 43213883)
6. Derogatis LR, Lipman RS, Covil L. SCL-90: An outpatient rating scale- Preliminary report. Psychopharmacol Bull 1973;9:13-28.
7. Gold MS, Pottash AD, Sweeney DR, et al. Lofexidine blocks acute opiate withdrawal. NIDA Res Monogr 1982;41:264-268.
8. Gold MS, Redmond DE Jr, Kleber HD. Clonidine blocks acute opiate withdrawal symptoms. Lancet 1978;2:599-602. (Pubitemid 9009208)
9. Maddux J. Methadone maintenance and recovery from opioid dependence. Am J Drug Alcohol Abuse 1992;18:63-74.
10. McCann MJ, Miotto K, Rawson R, et al. Outpatient non-opioid detoxification for opioid withdrawal. Am J Addict 1997;6:218-223. (Pubitemid 27356004)
11. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat 1992;9:199-213.
12. O'Connor PG, Carroll KM, Shi JM, et al. Three methods of opioid detoxification in a primary care setting. Ann Intern Med 1997;127:526-530. (Pubitemid 27419444)
13. O'Connor PG, Waugh ME, Carroll KM, et al. Primary care-based ambulatory opioid detoxification: Results of a clinical trial. J Gen Intern Med 1995;10:255-260.
14. O'Connor PG, Waugh ME, Schottenfeld RS, et al. Ambulatory opioid detoxification and primary care: A role for the primary care physician. J Gen Intern Med 1992;7:532-534.
15. Polydorou S, Kleber HD. Detoxification of Opioids. In: Galanter M, Kleber HD, eds. The American Psychiatric Publishing Textbook of Substance Abuse Treatment. Washington, DC: American Psychiatric Press, Inc., 2008:265-287.
16. Rajashekara V, Patel CN, Patel K, et al. Chronic opioid antagonist treatment dose-dependently regulates μ-opioid receptors and trafficking proteins in vivo. Pharmacol Biochem Behav 2003;75:909-913. (Pubitemid 37289477)
17. Resnick R. Naltrexone for Relapse Prevention in Opiate Dependent Treatment. Abstract Presented at the NIDA National Conference on Drug Abuse Research and Practice. Washington, DC; January 12-15, 1991.
18. Tamaskar R, Parran TB, Heggi A, et al. Tramodol versus buprenorphine for the treatment of opiate withdrawal: A retrospective cohort control study. J Addict Dis 2003;22:5-12. (Pubitemid 38174752)
19. Tennant FS Jr, Rawson RA. Guanabenz acetate: A new, long-acting alphatwo adrenergic agonist for opioid withdrawal. NIDA Res Monogr 1984;49:338-343. (Pubitemid 15019556)
20. Umbricht A, Leslie JM, Tucker MJ, et al. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug Alcohol Depend 2003;69:263-272. (Pubitemid 36293938)
21. Yu E, Herman BH, Miotto K, et al. An In-patient Phase I/II Study of Lofexidine (Alpha-2 Adrenergic Agonist) for Opiate Detoxification. Abstract presented at the 64th Annual Meeting of the College on Problems of Drug Dependence, Quebec City, Quebec; June 9, 2002.